Trial Profile
A Phase 1 Double-Blind (3rd Party Open), Randomized, Placebo-Controlled Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Feb 2019
Price :
$35
*
At a glance
- Drugs PF 3654764 (Primary) ; Fexofenadine
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Pfizer
- 28 Feb 2011 New trial record